CRV431

First NASH Patient Dosed with CRV431 in Phase 2 ‘AMBITION’ Clinical Trial

The ‘AMBITION' trial, is designed to assess safety, tolerability, and pharmacokinetics of 75 mg CRV431, administered orally to F2 and…

5 years ago

Hepion Pharmaceuticals’ CRV431 Demonstrates Efficacy in Kidney Fibrosis

CRV431 has exerted antifibrotic activity in a number of in vitro and in vivo studies conducted by independent research laboratories

5 years ago

This website uses cookies. Your continued use of the site is subject to the acceptance of these cookies. Please refer to our Privacy Policy for more information.